Company: KROS
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001664710-25-000089
Chunk: 228

Company: Keros Therapeutics, Inc.
Filing Date: 2025-11-05
Form: 10-Q
Item: Item 1
Chunk 228
---
 Non-cash lease expense1,788 1,248 Changes in operating assets and liabilities:Accounts receivable(750)(245)Prepaid expenses and other current assets3,877 (4,971)Other assets2,056 465 Accounts payable(2,304)44 Right-of-use assets and operating lease liabilities(1,432)(895)Deferred revenue155 — Current tax liability4,147 — Accrued expenses and other current liabilities(5,701)4,251 Net cash provided by (used in) operating activities134,797 (114,861)CASH FLOWS FROM INVESTING ACTIVITIES:Purchase of property and equipment(1,417)(1,642)Net cash used in investing activities(1,417)(1,642)CASH FLOWS FROM FINANCING ACTIVITIES:Proceeds from issuance of common stock, net of underwriting discounts— 151,340 Payment of issuance costs— (283)Proceeds from issuance of common stock under the ATM agreement, net of commissions— 155,695 Payment of issuance costs associated with issuance of common stock under the ATM agreement— (171)Proceeds from issuance of common stock under the employee stock purchase plan138 — Proceeds from exercise of stock options23 9,696 Net cash provided by financing activities161 316,277 NET INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH133,541 199,774 Cash, cash equivalents and restricted cash at beginning of period561,380 332,359 Cash, cash equivalents and restricted cash at end of period$694,921 $532,133 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:Cash paid for federal income taxes$2,250 $— Right-of-use assets obtained in exchange for operating lease obligation$— $5,737 Property and equipment purchases in accounts payable and accrued expenses$5 $86 

The following table provides a reconciliation of the ending cash, cash equivalents and restricted cash as of each of the periods shown above:

SEPTEMBER 30,20252024Cash and cash equivalents$693,472 $530,684 Restricted cash1,449 1,449 Total cash, cash equivalents and restricted cash$694,921 $532,133 

See notes to condensed consolidated financial statements.

8